Wisit Cheungpasitporn1, Charat Thongprayoon2, Patompong Ungprasert3, Karn Wijarnpreecha4, Michael A Mao5, Narothama Reddy Aeddula6, Wisit Kaewput7, Tarun Bathini8, Paul T Kroner4. 1. Division of Nephrology, Department of Medicine, University of Mississippi Medical Center, Jackson, Mississippi. 2. Division of Nephrology, Department of Medicine, Mayo Clinic, Rochester, Minnesota. 3. Department of Rheumatic and Immunologic Diseases, Cleveland Clinic Lerner, College of Medicine of Case Western Reserve University, Cleveland Clinic, Cleveland, Ohio. 4. Division of Gastroenterology and Hepatology. 5. Division of Nephrology, Department of Medicine, Mayo Clinic, Jacksonville, Florida. 6. Division of Nephrology, Department of Medicine, Deaconess Health System, Evansville, Indiana, USA. 7. Department of Military and Community Medicine, Phramongkutklao College of Medicine, Bangkok, Thailand. 8. Department of Internal Medicine, University of Arizona, Tucson, Arizona, USA.
Abstract
BACKGROUND: This study aimed to evaluate the hospitalization rate for Hepatitis A virus (HAV) among kidney transplant (KTx) recipients and its outcomes as well as resource utilization. METHODS: The 2005-2014 National Inpatient Sample database was used to identify all hospitalized KTx recipients with an associated diagnosis of HAV. The hospital mortality, resource utilization, and associated liver conditions were compared between patients with and without HAV, adjusting for potential confounders. RESULTS: Of 871 024 KTx recipients identified, 204 had HAV. The overall inpatient prevalence of HAV in KTx recipients over 10 years in the United States was 23.42 cases per 100 000 admissions. There were no statistically significant changes in the inpatient prevalence of HAV in KTx recipients during the study period (P = 0.77), ranging from 9.2 to 34.3 per 100 000 admissions. Among hospitalized KTx recipients with HAV, 27.9% were from Northeast, 29.2% were from Midwest, 23.8% were from South, and 19.1% were from West. HAV was not significantly associated with increased hospital mortality, multiorgan failure, need for abdominal ultrasound, hospital length of stay, and total hospitalization costs and charges when compared with those without HAV. However, it is significantly associated with increased ICU stay, coexisting hepatitis B and C infection, and liver failure. CONCLUSION: Overall, inpatient prevalence of HAV in KTx recipients in the United States (years 2005-2014) was 23.42 cases per 100 000 admissions. Hospitalization for HAV after KTx is associated with increased ICU stay, coexisting hepatitis B and C infection, and liver failure.
BACKGROUND: This study aimed to evaluate the hospitalization rate for Hepatitis A virus (HAV) among kidney transplant (KTx) recipients and its outcomes as well as resource utilization. METHODS: The 2005-2014 National Inpatient Sample database was used to identify all hospitalized KTx recipients with an associated diagnosis of HAV. The hospital mortality, resource utilization, and associated liver conditions were compared between patients with and without HAV, adjusting for potential confounders. RESULTS: Of 871 024 KTx recipients identified, 204 had HAV. The overall inpatient prevalence of HAV in KTx recipients over 10 years in the United States was 23.42 cases per 100 000 admissions. There were no statistically significant changes in the inpatient prevalence of HAV in KTx recipients during the study period (P = 0.77), ranging from 9.2 to 34.3 per 100 000 admissions. Among hospitalized KTx recipients with HAV, 27.9% were from Northeast, 29.2% were from Midwest, 23.8% were from South, and 19.1% were from West. HAV was not significantly associated with increased hospital mortality, multiorgan failure, need for abdominal ultrasound, hospital length of stay, and total hospitalization costs and charges when compared with those without HAV. However, it is significantly associated with increased ICU stay, coexisting hepatitis B and C infection, and liver failure. CONCLUSION: Overall, inpatient prevalence of HAV in KTx recipients in the United States (years 2005-2014) was 23.42 cases per 100 000 admissions. Hospitalization for HAV after KTx is associated with increased ICU stay, coexisting hepatitis B and C infection, and liver failure.
Authors: Christophe Masset; Paul Le Turnier; Céline Bressollette-Bodin; Karine Renaudin; François Raffi; Jacques Dantal Journal: Int J Mol Sci Date: 2022-10-10 Impact factor: 6.208